Close Menu

COLUMBIA, Md.--Gene Logic here has announced that it will collaborate with Japan Tobacco to uncover drug targets and leads in kidney disease. Gene Logic will utilize its proprietary Accelerated Drug Discovery platform in the effort. Japan Tobacco will also be the first subscriber to Gene Logic's Gene Express Normal database of quantitative gene expression profiles in a variety of normal tissues of human, rat, and mouse origin. The deal also gives Japan Tobacco the option of accessing Gene Logic's Flow-thru Gene Chip technology for high-throughput screening.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.

May
07
Sponsored by
Agilent

This webinar will discuss the implementation of an enterprise-wide clinical genomics platform that is shared across 10 hospitals and research organizations in the Australian State of Victoria.